Related references
Note: Only part of the references are listed.Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease
Bruce E. Sands et al.
GASTROENTEROLOGY (2022)
Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials
Shomron Ben-Horin et al.
GASTROENTEROLOGY (2022)
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study
William J. Sandborn et al.
GASTROENTEROLOGY (2022)
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
Quazim A. Alayo et al.
CROHNS & COLITIS 360 (2022)
Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease
Carlos Stalgis et al.
GASTROENTEROLOGY (2021)
AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2021)
Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics
Konstantinos H. Katsanos et al.
GUT AND LIVER (2017)
25th UEG Week 2017 Barcelona, Spain, October 2017 Abstracts
[Anonymous]
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2017)
Biologic agents for IBD: practical insights
Silvio Danese et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Biologics in inflammatory bowel disease: what are the data?
Justin Cote-Daigneault et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2015)
Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
Bruce E. Sands et al.
GASTROENTEROLOGY (2014)
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
Paul Rutgeerts et al.
GASTROENTEROLOGY (2012)
Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
Mamoru Watanabe et al.
JOURNAL OF CROHNS & COLITIS (2012)
Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
David Moher et al.
INTERNATIONAL JOURNAL OF SURGERY (2010)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients:: A randomized placebo-controlled trial
M Lémann et al.
GASTROENTEROLOGY (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2005)